정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1577 | Recruiting | Efficacy and Safety of Sirolimus in COVID-19 Infection | COVID 19 | Drug: Sirolimus | Phase 2 | Alexandria University | OTHER | 40 | All | 18 Years | Faculty of Medicine, Alexandria university, Egypt, Alexandria, Egypt |
| 1576 | Recruiting | Efficacy and Safety of Three Different Doses of an Anti SARS-CoV-2 Hyperimmune Equine Serum in COVID-19 Patients | Covid19 | Biological: Anti SARS-CoV-2 equine hyperimmune serum Biological: placebo |
Phase 3 | Caja Costarricense de Seguro Social, Universidad de Costa Rica, Ministry of Health Costa Rica | OTHER_GOV | 156 | All | 18 Years | Centro Especializado de Atencion COVID19 (CEACO), San Jose, Costa Rica Hospital Dr. Rafael Angel Calderon Guardia, San Jose, Costa Rica Hospital Mexico, San Jose, Costa Rica Hospital San Juan de Dios, San Jose, Costa Rica |
| 1575 | Completed | Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia | COVID-19 | Drug: Tofacitinib | Phase 2 | I.M. Sechenov First Moscow State Medical University | OTHER | 414 | All | 18 Years | Sechenov First Moscow State Medical University (Sechenov University) - University Clinical Hospital, Moscow, Russian Federation |
| 1574 | Active, not recruiting | Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19 | Covid19 | Drug: Trimodulin Other: Placebo (human albumin 1%) |
Phase 2 | Biotest | INDUSTRY | 164 | All | 18 Years | Investigational site # 5503, Porto Alegre, Brazil Investigational site # 5502, Santo Andre, Brazil Investigational site # 5505, Santo Andre, Brazil Investigational site # 5501, Sao Paulo, Brazil Investigational site # 3304, Paris, France Investigational Site # 3301, Paris, France Investigational site # 3305, Saint-Etienne, France Investigational site # 0707, Kemerovo, Russian Federation Investigational site # 0709, Krasnoyarsk, Russian Federation Investigational site # 0702, Moscow, Russian Federation Investigational site # 0706, Moscow, Russian Federation Investigational site # 0711, Moscow, Russian Federation Investigational Site # 0704, Moscow, Russian Federation Investigational site # 0708, Moscow, Russian Federation Investigational site # 0701, Saint Petersburg, Russian Federation Investigational Site # 3401, Barcelona, Spain Investigational Site # 3402, Madrid, Spain |
| 1573 | Completed | Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients | Covid19 | Biological: Administration of Equine immunoglobulin anti SARS-CoV-2 | Phase 2 | Caja Costarricense de Seguro Social, Universidad de Costa Rica, Ministry of Health Costa Rica | OTHER_GOV | 26 | All | 18 Years | Centro Especializado de Atencion COVID19 (CEACO), San Jose, Costa Rica Hospital Dr. Rafael Angel Calderon Guardia, San Jose, Costa Rica Hospital Mexico, San Jose, Costa Rica Hospital San Juan de Dios, San Jose, Costa Rica |
| 1572 | Recruiting | Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans | Coronavirus Disease-2019 (COVID-19) | Biological: TY027 Biological: TY027 Other: 0.9% saline |
Phase 3 | Tychan Pte Ltd. | INDUSTRY | 1305 | All | 21 Years ~ 100 Years | Singapore General Hospital, Singapore, Singapore |
| 1571 | Completed | Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19 | Supportive Care | Dietary Supplement: Viusid Dietary Supplement: Asbrip Drug: Standard Care |
Phase 2 | Catalysis SL | INDUSTRY | 60 | All | 18 Years | MBAL, Sv. Mina, Plovdiv, Bulgaria MTB Plovdiv, Plovdiv, Bulgaria |